Literature DB >> 32938780

Teaching NeuroImages: Cytotoxic lesions of the corpus callosum in encephalopathic patients with COVID-19.

Myriam Edjlali1, Aurélie Le Gal2, Martin Louvet2, Morgan Matt2, Christophe Leveque2, Caroline Diffre2, David Orlikowski2, Djillali Annane2, Robert-Yves Carlier2.   

Abstract

Entities:  

Year:  2020        PMID： 32938780     DOI： 10.1212/WNL.0000000000010880

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

1.  Reversible Cytotoxic Lesion of the Corpus Callosum and COVID-19.

Authors:  Jesús Garcia Castro; Cristina Utrilla Contreras; Ángel Martín Montes
Journal:  Neurohospitalist       Date:  2022-05-17

Review 2.  COVID-19 and neuroinflammation: a literature review of relevant neuroimaging and CSF markers in central nervous system inflammatory disorders from SARS-COV2.

Authors:  Shitiz Sriwastava; Medha Tandon; Sanjiti Podury; Apoorv Prasad; Sijin Wen; Garret Guthrie; Mihir Kakara; Shruti Jaiswal; Roshan Subedi; Mahmoud Elkhooly; Robert P Lisak
Journal:  J Neurol       Date:  2021-05-19       Impact factor: 6.682

3.  Postmortem brain 7T MRI with minimally invasive pathological correlation in deceased COVID-19 subjects.

Authors:  Maria da Graça Morais Martin; Vitor Ribeiro Paes; Ellison Fernando Cardoso; Carlos Eduardo Borges Passos Neto; Cristina Takami Kanamura; Claudia da Costa Leite; Maria Concepcion Garcia Otaduy; Renata Aparecida de Almeida Monteiro; Thais Mauad; Luiz Fernando Ferraz da Silva; Luiz Henrique Martins Castro; Paulo Hilario Nascimento Saldiva; Marisa Dolhnikoff; Amaro Nunes Duarte-Neto
Journal:  Insights Imaging       Date:  2022-01-15

4.  Early Neurorehabilitation and Recovery from Disorders of Consciousness After Severe COVID-19.

Authors:  Lindsey Gurin; Megan Evangelist; Patricia Laverty; Kaitlin Hanley; John Corcoran; Jodi Herbsman; Brian Im; Jennifer Frontera; Steven Flanagan; Steven Galetta; Ariane Lewis
Journal:  Neurocrit Care       Date:  2021-10-05       Impact factor: 3.532
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.